Augmedix, Inc.
AUGX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | -0.26 | 2.97 | 0.69 |
| FCF Yield | -8.56% | -4.13% | -0.76% | -1.16% |
| EV / EBITDA | -6.39 | -33.80 | -65.89 | -67.71 |
| Quality | ||||
| ROIC | -23.48% | -14.37% | -8.46% | -10.84% |
| Gross Margin | 47.24% | 47.07% | 49.26% | 49.55% |
| Cash Conversion Ratio | 0.46 | 1.27 | 0.22 | 0.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.83% | 25.97% | 26.49% | 26.68% |
| Free Cash Flow Growth | 51.72% | -306.46% | 20.66% | 62.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.40 | 1.97 | 5.07 | 0.63 |
| Interest Coverage | -13.65 | -10.39 | -6.74 | -6.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -2.92 |
| Cash Conversion Cycle | 49.94 | 50.95 | 50.76 | 13.93 |